Amgen (AMGN) Stock Looks Cheap Relative To Fair Value

Amgen stock has more than doubled over the past five years, yet current valuation checks still lean toward the shares trading below an intrinsic value estimate based on a Discounted Cash Flow model and on earnings multiples. Recent clinical wins in oncology and cardiovascular disease sit alongside a pullback in the share price over the past week and month, which leaves investors weighing strong long term gains against signals that the stock may still be priced below its underlying cash flow potential.

• Over the last 5 years, Amgen has delivered a total return of 109.6%, which puts recent short term weakness in the context of a strong long term run for holders.
• New trial results for IMDELLTRA and Repatha can support expectations for future cash flows, while uncertainty around Amgen's Lp(a) program after Novartis' pelacarsen setback may limit how much value investors are willing to ascribe to that part of the pipeline.
• The Discounted Cash Flow intrinsic value estimate sits about 41.9% above the recent share price and aligns with earnings based checks, while the broader valuation score of 4 out of 6 points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Amgen's current price already reflects the recent drug data and pipeline risks or if the gap to intrinsic value leaves room for further upside over time.

Spot opportunities beyond Amgen by scanning high conviction ideas in the 31 high quality undervalued stocks that combine solid fundamentals with valuations that still leave room for sentiment to catch up.

Is Amgen a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Amgen can return to shareholders over time. Latest twelve month free cash flow is about $10.8b, which supports the use of a 2 stage Free Cash Flow to Equity approach with growing cash flows rather than a turnaround story. On that basis, the intrinsic value comes out at roughly $673 per share.

That estimate sits about 41.9% above the recent market price, which indicates a meaningful gap between Amgen’s trading level and the DCF output, even after a strong multiyear run. The Phase 3 DeLLphi-305 result for IMDELLTRA, with a reported improvement in overall survival in small cell lung cancer, is one specific recent development that some investors may consider when comparing the current share price to the modeled valuation.

On these cash flow assumptions, Amgen appears undervalued relative to the DCF-based intrinsic value estimate.

Our Discounted Cash Flow (DCF) analysis suggests Amgen is undervalued by 41.9%. Track this in your watchlist or portfolio, or discover 31 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Amgen.

Does Amgen Look Undervalued on Earnings?

P/E works well for Amgen because earnings remain a central yardstick for how investors price large, profitable drug developers. On this measure, the stock trades on roughly 24.2x earnings, which is below the peer group average of about 39.2x but above the broader biotech industry on roughly 16.8x. That combination shows the market is willing to pay a premium over the sector as a whole, while still applying a discount to similar large biopharma peers.

A tailored fair P/E ratio for Amgen of about 30.0x reflects what investors might pay given its size, margins and risk profile. The current 24.2x mark sits meaningfully under that fair multiple, leaving a gap that points to a lower price tag than this framework implies.

On earnings, Amgen appears undervalued, with the current P/E sitting below the fair multiple suggested by its fundamentals and peer group.

See what the numbers say about this price — find out in our valuation breakdown.

The Amgen Narrative: What Would Justify Today's Price?

Amgen’s Simply Wall St Narratives pick up where this valuation puzzle leaves off. They spell out which assumptions on future growth, profitability and earnings would need to hold for the stock to be worth materially more or materially less than today’s price, and each one treats fair value as a hypothesis about Amgen’s business that you can revisit over time, rather than a one off snapshot. These are available on Simply Wall St’s Community page.

Community views on Amgen pull in opposite directions, with one camp leaning into the breadth of the pipeline and another focused on erosion risk around older therapies.

Bull case: 14% undervalued

"The company's extensive global footprint, growing access initiatives, and direct-to-consumer strategies position its therapies for accelerated uptake among the rapidly expanding populations affected by aging and lifestyle-related chronic diseases..."

Read the full Bull Case to see why Amgen could be undervalued

Bear case: 9% overvalued

"MariTide's commercial ramp-up will take years post-launch, while Amgen’s high-margin legacy moats (Prolia and Enbrel) are already eroding at a brutal 30%+ year-over-year clip right now..."

Read the full Bear Case to see why Amgen could be overvalued

Do you think there's more to the story for Amgen? Head over to our Community to see what others are saying!

The Bottom Line

Amgen screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on earnings multiples, which points to a consistent message rather than a one off quirk of the models. The gap between price and intrinsic value suggests the market is still cautious about how much of the pipeline eventually converts into durable cash generation. For investors, everything now hinges on one question: Do the recent oncology and cardiovascular data points evolve into dependable, long term cash flows that close this discount, or does pipeline and erosion risk prove the current markdown is justified?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com